Aytu BioPharma IncAYTU
Price$2.14

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $56.6M-13.2% YoYTTM through 31 Mar 2026
Net Income -$34.1MTTM through 31 Mar 2026
Free Cash Flow $1.6MTTM through 31 Mar 2026

Margins

Current
Gross Margin61.0%
EBITDA Margin-19.2%
Operating Margin-33.1%
Net Margin-60.2%

Returns

-97.0%ROE
-30.5%ROA

Balance Sheet Health

Debt / Equity0.32x
Current Ratio1.12x
Net Debt-$4.7Mnet cash position
Cash & Equivalents$26.7M

Quality Metrics

Altman Z-Score-4.03
Piotroski F-Score2 / 9
FCF Margin2.9%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'20'21'22'23'24'25
FY2025: $66.4M
Diluted EPS
'21'22'23'24'25
FY2025: $-2.16

Dividend

No dividend

Capital Allocation

R&D Spend$216K
Capex Intensity0.1%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.